Nick Stone

Nick has more than 20 years of healthcare sector experience. On October 1, 2024 he joined Fresenius SE & Co. KGaA as Head of Investor Relations, Senior Vice President. Before this he was Head of Investor Relations at GSK plc, and prior to this he was Director of Investor Relations at AstraZeneca plc. Nick has been accountable for investor outreach and engagement in North America, Europe, Asia Pacific and ESG. He has also overseen more than $200 billion in business development transactions, including the demerger of GSK plc’s consumer healthcare business to form Haleon plc, the $39 billion acquisition of Alexion Pharmaceuticals, Inc., a rare disease company, and an equity placing of $3.5 billion gaining access to trastuzumab deruxtecan, a novel anti-drug conjugate from Daiichi Sankyo Company Ltd.

Prior to investor relations at AstraZeneca, Nick was Director of in-line indications for Brilinta, a medicine used to treat patients who have suffered from a heart attack. Before moving to the commercial organisation, he was a Director of Business Development leading both buy and sell-side licensing and M&A transactions in the Regional and Corporate Business Development Team.

Before this role, Nick was appointed principal Corporate Strategist, based in London, where he provided a range of advisory services to the Senior Executive Team and Board.

In 2005, Nick took a sabbatical to compete in the Clipper Round the World Yacht Race. He began his early career as an Associate Lawyer, graduating with a bachelor’s degree with honours in Law and Criminology before taking his Legal Practice Course.